Metagenomi, Inc. Common Stock
Metagenomi, Inc. Common Stock
Your view on MGX
Overview
What the company does, where it operates, and who runs it.
About Metagenomi, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jian Irish
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jian Irish
- Headquarters
- US
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.
The company was incorporated in 2016 and is based in Emeryville, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Metagenomi, Inc. Common Stock, and the rating behind it. MGX last traded at $1.16; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Metagenomi, Inc. Common Stock. Starting points for Metagenomi, Inc. Common Stock: EPS -$2.48, beta 0.68 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Metagenomi, Inc. Common Stock. Metagenomi, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Metagenomi, Inc. Common Stock. Trailing twelve-month EPS for Metagenomi, Inc. Common Stock stands at -$2.48. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Metagenomi, Inc. Common Stock. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Metagenomi, Inc. Common Stock valued side by side against its closest peers. Metagenomi, Inc. Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Metagenomi, Inc. Common Stock, and how their positions are changing. At a $43.7M market value, institutional positions materially move Metagenomi, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Metagenomi, Inc. Common Stock executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Metagenomi, Inc. Common Stock. Metagenomi, Inc. Common Stock is a $43.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Metagenomi, Inc. Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Metagenomi, Inc. Common Stock. Coverage tracks Metagenomi, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.